![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Saturday, January 01, 2005 10:54:54 AM
From 10K:
We expect to be subject to increased foreign currency risk in our international operations.
In 2003, approximately 34% of our revenues were denominated in euros, primarily related to sales from our Dresden operation, including sales to one of our largest customers, a European automotive glass manufacturer. In addition, other customers may request to make payments in foreign currencies. Also, certain transactions with foreign suppliers are denominated in foreign currencies, primarily Japanese Yen.
A strengthening in the dollar relative to the currencies of those countries in which we do business would increase the prices of our products as stated in those currencies and could hurt our sales in those countries. Significant fluctuations in the exchange rates between the U.S. dollar and foreign currencies could cause us to lower our prices and thus reduce our profitability and cash flows. These fluctuations could also cause prospective customers to cancel or delay orders because of the increased relative cost of our products.
Recent SWTX News
- SpringWorks Therapeutics Completes Submission of New Drug Application to the FDA for Mirdametinib for the Treatment of Children and Adults with NF1-PN • GlobeNewswire Inc. • 07/01/2024 10:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/07/2024 08:15:30 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/05/2024 08:07:38 PM
- SpringWorks Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference • GlobeNewswire Inc. • 06/05/2024 11:00:52 AM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 06/03/2024 08:37:20 PM
- SpringWorks Therapeutics Announces Data to be Presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting • GlobeNewswire Inc. • 05/23/2024 09:13:28 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/17/2024 08:53:56 PM
- SpringWorks Therapeutics to Participate in the BofA Securities 2024 Health Care Conference • GlobeNewswire Inc. • 05/08/2024 11:00:27 AM
- SpringWorks Therapeutics Reports First Quarter 2024 Financial Results and Highlights Recent Business Updates • GlobeNewswire Inc. • 05/02/2024 10:30:00 AM
- SpringWorks Therapeutics Announces Abstracts Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting • GlobeNewswire Inc. • 04/24/2024 05:31:32 PM
- SpringWorks Therapeutics to Report First Quarter 2024 Financial Results Thursday, May 2, 2024 • GlobeNewswire Inc. • 04/18/2024 11:00:28 AM
- SpringWorks Therapeutics Initiates Rolling Submission of New Drug Application to the FDA for Mirdametinib for the Treatment of Children and Adults with NF1-PN • GlobeNewswire Inc. • 03/04/2024 11:30:11 AM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/01/2024 10:16:11 PM
- SpringWorks Therapeutics Announces European Medicines Agency Validation for Marketing Authorization Application of Nirogacestat for the Treatment of Adults with Desmoid Tumors • GlobeNewswire Inc. • 02/29/2024 01:30:13 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/27/2024 01:28:17 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 02/27/2024 01:23:12 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 02/27/2024 12:29:18 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 02/27/2024 11:51:44 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/27/2024 11:44:27 AM
- SpringWorks Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Business Updates • GlobeNewswire Inc. • 02/27/2024 11:30:00 AM
- SpringWorks Therapeutics to Present at Upcoming Investor Conferences • GlobeNewswire Inc. • 02/22/2024 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/20/2024 11:56:43 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 02/16/2024 06:09:51 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/14/2024 01:56:14 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/06/2024 02:24:32 AM
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM
VAYK Exited Caribbean Investments for $320,000 Profit • VAYK • Jun 27, 2024 9:00 AM
North Bay Resources Announces Successful Flotation Cell Test at Bishop Gold Mill, Inyo County, California • NBRI • Jun 27, 2024 9:00 AM
Branded Legacy, Inc. and Hemp Emu Announce Strategic Partnership to Enhance CBD Product Manufacturing • BLEG • Jun 27, 2024 8:30 AM
POET Wins "Best Optical AI Solution" in 2024 AI Breakthrough Awards Program • POET • Jun 26, 2024 10:09 AM